This biomarker is also known as:
- PCCase subunit alpha,
- propionyl-CoA carboxylase alpha chain, mitochondrial,
- PCCase alpha subunit,
- EC 184.108.40.206,
- Propanoyl-CoA:carbon dioxide ligase subunit alpha,
- propionyl CoA carboxylase, alpha polypeptide,
- pccA complementation group,
- propanoyl-CoA:carbon dioxide ligase alpha subunit,
- propionyl Coenzyme A carboxylase, alpha polypeptide,
View in BioMuta
PCCA, or propionyl CoA carboxylase, alpha polypeptide, is the alpha subunit of the heterodimeric mitochondrial enzyme Propionyl-CoA carboxylase. The beta subunit is PCCB. The enzyme deficiency propionic acidemia results from mutations in either PCCA or PCCB. Several isoforms for this gene have been identified, coded by multiple transcript variants.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional breast data available.
PCCA was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.